Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP031112 in mild-to-moderate progressive supranuclear palsy
2009-013097-40Phase 2Completed
- Sponsor
- Noscira S.A.
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tideglusib in progressive supranuclear palsy (PSP) (3 arms), sponsored by Noscira S.A. Primary endpoints: Change from baseline in Progressive Supranuclear Palsy Rating Scale of Golbe at 52 weeks and Safety and tolerability over 52 weeks. Started Jul 2009; status: completed.
02
Drugs
tideglusib
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on 2009-013097-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013097-40.